Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)
Close on Nov 13, 2026Market cap $122.21MP/E –Yield –
Journey Medical total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Journey Medical's total debt was $25.58M at Sep 30, 2026. For fiscal 2025 it was $25.28M, up 1.6% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.28M | +1.6% |
| FY2024 | Dec 31, 2024 | $24.88M | +70.1% |
| FY2023 | Dec 31, 2023 | $14.62M | -26.2% |
| FY2022 | Dec 31, 2022 | $19.83M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $25.58M | +1.7% |
| Q2 FY2026 | Jun 30, 2026 | $25.47M | +1.4% |
| Q1 FY2026 | Mar 31, 2026 | $25.37M | +1.6% |
| Q4 FY2025 | Dec 31, 2025 | $25.28M | +1.6% |
| Q3 FY2025 | Sep 30, 2025 | $25.16M | +27.2% |
| Q2 FY2025 | Jun 30, 2025 | $25.11M | +27.2% |
| Q1 FY2025 | Mar 31, 2025 | $24.98M | +70.1% |
| Q4 FY2024 | Dec 31, 2024 | $24.88M | +70.1% |
| Q3 FY2024 | Sep 30, 2024 | $19.79M | +99.0% |
| Q2 FY2024 | Jun 30, 2024 | $19.75M | -0.4% |
| Q1 FY2024 | Mar 31, 2024 | $14.68M | -25.9% |
| Q4 FY2023 | Dec 31, 2023 | $14.62M | -1.2% |
| Q2 FY2023 | Jun 30, 2023 | $9.94M | -32.7% |
| Q4 FY2022 | Dec 31, 2022 | $19.83M | – |
| Q3 FY2022 | Sep 30, 2022 | $19.81M | – |
| Q2 FY2022 | Jun 30, 2022 | $14.79M | – |
| Q1 FY2022 | Mar 31, 2022 | $14.78M | – |
See a number that looks wrong?